Triple

T7392989
Position Surface form Disambiguated ID Type / Status
Subject George Church E170546 entity
Predicate coFounded P104 FINISHED
Object Dyno Therapeutics
Dyno Therapeutics is a biotechnology company that uses artificial intelligence and machine learning to design optimized adeno-associated virus (AAV) gene therapy vectors.
E661993 NE FINISHED

How this triple was built (4 steps)

Every LLM step that produced this triple, in pipeline order — named-entity classification, the disambiguation choices (the exact options shown, with the pick highlighted), and the generated description. The batch + timestamp of each is in the Provenance table below.

NER Named-entity recognition gpt-5-mini
Instruction
Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).
Input
Phrase: Dyno Therapeutics | Statement: [George Church, coFounded, Dyno Therapeutics]
NED1 Entity disambiguation (via context triple) gpt-5-mini-2025-08-07
Target entity: Dyno Therapeutics
Context triple: [George Church, coFounded, Dyno Therapeutics]
  • A. Insitro
    Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
  • B. Nautilus Biotechnology
    Nautilus Biotechnology is a life sciences company developing next-generation, high-throughput proteomics platforms to enable comprehensive analysis of the human proteome for research and drug discovery.
  • C. Ridgeback Biotherapeutics
    Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
  • D. Juno Therapeutics
    Juno Therapeutics is a biotechnology company focused on developing cutting-edge immunotherapies, particularly CAR-T cell treatments, for cancer.
  • E. Array BioPharma
    Array BioPharma is a biopharmaceutical company known for developing targeted small-molecule cancer therapies, particularly in oncology and rare diseases.
  • F. None of above. chosen
  • G. Unsure - the case is ambiguous/there is not enough information to decide.
NEDg Description generation gpt-5.1
Instruction
Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"
Input
Entity: Dyno Therapeutics
Triple: [George Church, coFounded, Dyno Therapeutics]
Generated description
Dyno Therapeutics is a biotechnology company that uses artificial intelligence and machine learning to design optimized adeno-associated virus (AAV) gene therapy vectors.
NED2 Entity disambiguation (via description) gpt-5-mini-2025-08-07
Target entity: Dyno Therapeutics
Target entity description: Dyno Therapeutics is a biotechnology company that uses artificial intelligence and machine learning to design optimized adeno-associated virus (AAV) gene therapy vectors.
  • A. Insitro
    Insitro is a biotechnology company that uses machine learning and high-throughput biology to accelerate drug discovery and development.
  • B. Nautilus Biotechnology
    Nautilus Biotechnology is a life sciences company developing next-generation, high-throughput proteomics platforms to enable comprehensive analysis of the human proteome for research and drug discovery.
  • C. Ridgeback Biotherapeutics
    Ridgeback Biotherapeutics is a biotechnology company focused on developing antiviral and immunotherapy treatments for serious infectious diseases, including Ebola and COVID-19.
  • D. Juno Therapeutics
    Juno Therapeutics is a biotechnology company focused on developing cutting-edge immunotherapies, particularly CAR-T cell treatments, for cancer.
  • E. Array BioPharma
    Array BioPharma is a biopharmaceutical company known for developing targeted small-molecule cancer therapies, particularly in oncology and rare diseases.
  • F. None of above. chosen

Provenance (5 batches)

The batch behind each pipeline step, in order, with when it ran. Timestamps are batch-level — stages were processed in waves, so the object chain (NER → NED1 → NEDg → NED2) reads in order, but predicate / elicitation batches can sit in a different wave.

Step Stage Batch ID Status When
creating Elicitation batch_69c68a5e2c9081909e713ce866e0060a completed March 27, 2026, 1:47 p.m.
NER Named-entity recognition batch_69c6f224790c819099ceb7c7ac8d00f6 completed March 27, 2026, 9:09 p.m.
NED1 Entity disambiguation (via context triple) batch_69c810f82ba08190919924b0994a2eee completed March 28, 2026, 5:33 p.m.
NEDg Description generation batch_69c811f1fe3c8190a591186b19044b5f completed March 28, 2026, 5:37 p.m.
NED2 Entity disambiguation (via description) batch_69c812c1e9d08190b0e7f052d87011b9 completed March 28, 2026, 5:41 p.m.
Created at: March 27, 2026, 3:09 p.m.